When was Thermona founded?

Thermona was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is Thermona located?

Thermona is headquartered in Beijing, China.

Is Thermona a funded company?

Thermona is a funded company, having raised a total of $60M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 2021.

When was the latest funding round of Thermona?

Thermona's latest funding was a $***** Series A round on Jun 20, 2022, with participation from 5 investors. Its primary sector is Immunotherapy. In China, the Immunotherapy sector has seen $359M in funding in 2026 to date.

Where does Thermona rank among its competitors?

Thermona ranks 116th amongst 360 active competitors, of which 94 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Ascletis Pharma, which secured $108M in Feb, 2026.

Who are the top competitors of Thermona?

Thermona's top competitors include Bharat Biotech, Tonix Pharma and HOOKIPA Pharma. Among them, Ascletis Pharma secured the most recent funding round in February, 2026.

Thermona - 2026 Company Profile, Team, Funding & Competitors

Thermona is a series A company based in Beijing (China), founded in 2021 by Wei Wensheng. It operates as a Developer of RNA technology-based drugs to address various diseases. Thermona has raised $60M in funding from MSA Capital. The company has 360 active competitors, including 94 funded and 90 that have exited. Its top competitors include companies like Bharat Biotech, Tonix Pharma and HOOKIPA Pharma.

Company Details

Developer of RNA technology-based drugs to address various diseases. The company focuses on the development of vaccines and treatments using circular RNA technology against the new coronavirus and its variants. Also, it is developing therapeutic proteins or polypeptides for rare diseases and cancer treatment.

Website: therorna.com
Email ID: *****@therorna.com

Key Metrics

Founded Year

2021

Location

Beijing, China

Stage

Series A

Total Funding

$60M in 3 rounds

Latest Funding Round

Series A, Jun 20, 2022, $*****

Investors

MSA Capital & 6 more

Ranked

116^th among 360 active competitors

Similar Companies

Bharat Biotech & 440 more

View Thermona's full profile

Thermona has raised a total funding of $60M over 3 rounds. Its first funding round was on Nov 2021. Its latest funding round was a Series A round on Jun 20, 2022 for $*****. 5 investors participated in its latest round. Thermona has 7 institutional investors.

Here is the list of recent funding rounds of Thermona:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 20, 2022	3813389	Series A	6410439	6118347	2450384	3163294
May 11, 2022	9594973	Seed	6074057	4852677	9343530	Tencent
Nov 2021	7509025	Seed	3026664	9680737	7045573	Quan Capital

Access funding benchmarks and valuations. Sign up today!

View details of Thermona's funding rounds and investors

The founders of Thermona is Wei Wensheng.

Here are the details of Thermona's key team members:

Wei Wensheng: Founder of Thermona.

View details of Thermona's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Thermona include Bharat Biotech, Tonix Pharma and HOOKIPA Pharma. Here is the list of Top 10 competitors of Thermona, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bharat Biotech 1996, Hyderabad (India), Early Stage	Manufacturer of vaccines and bio-therapeutic products	$13.7M	ICICI Venture, IFC & 25 others	68/100
2nd	Tonix Pharma 2007, New York City (United States), Public	Developer of next-generation medicines for CNS and immunological disorders	$4.45M	Westwicke, Technology Partners & 2 others	66/100
3rd	HOOKIPA Pharma 2011, Vienna (Austria), Public	Developer of immunotherapies for the treatment of infectious diseases and cancer	$134M	Sofinnova Partners, Forbion & 12 others	65/100
4th	Vaxart 2004, San Francisco (United States), Public	Developer of therapeutic solutions for treating multiple infectious diseases	$58M	Quantum Technology Partners, Life Science Angels ... & 8 others	64/100
5th	Valneva 1999, Lyon (France), Public	Developer of prophylactic vaccines for infectious diseases	$114M	Phase4 Partners, Eiffel Investment Group ... & 13 others	63/100
6th	Ascletis Pharma 2011, Hangzhou (China), Public	Developer of small molecules for the treatment of multiple diseases	$255M	CBC Group, Goldman Sachs & 5 others	62/100
7th	eradivir 2020, West Lafayette (United States), Series A	Developer of immunotherapies for the treatment of infectious diseases	$20.4M	Research Bridge Partners, America’s Seed Fund ... & 3 others	62/100
8th	Ocugen 2013, Aurora (United States), Public	Developer of therapeutic solutions to treat various eye disorders	-	Checkmate Capital, Colorado Office of Economic Development and International Trade ... & 5 others	61/100
9th	Brii Biosciences 2018, San Francisco (United States), Public	Developer of biologics to treat hepatitis B infection	$415M	HongShan, Invesco & 7 others	60/100
10th	SAB Biotherapeutics 2014, Sioux Falls (United States), Public	Developer of immunotherapeutics to treat infectious and autoimmune diseases	$49M	Merck, SD Equity Partners & 5 others	60/100
116th	Thermona 2021, Beijing (China), Series A	Developer of RNA technology-based drugs to address various diseases	$60M	MSA Capital, 3H Health Investment & 5 others	40/100